Please assess the completion status of the following clinical trial:

Trial Title: Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (MM)~* Eligible for autologous transplantation~* Patients in first or second partial remission (PR) or complete remission (CR)~* Patients who have received ≦2000 rads of prior radiation therapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Recovered from all acute toxic effects of prior chemotherapy~* White blood cells (WBC) \>3.0\*10\^9/l~* Absolute polymorphonuclear leucocyte (PMN) count \>1.5\*10\^9/l~* Platelet (PLT) count \> 150\*10\^9/l~* Serum creatinine ≦2.2 mg/dl~* Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin \<2 x upper limit of normal (ULN)~* Negative for HIV~* Signed informed consent~* Patients of childbearing potential agree to use an approved form of contraception~Exclusion Criteria:~* Patient received 2 or more alkylating agents, such as VBMCP (a combination of Vincristine, BCNU (Bis-Chloronitrosourea), Melphalan, Cyclophosphamide, and Prednisone)~* Patient received a total dose of ≧200 mg of prior melphalan~* A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications~* Patient has failed previous collections or collection attempts~* A residual acute medical condition resulting from prior chemotherapy~* Brain metastases or carcinomatous meningitis~* Acute infection~* Fever (temperature \>38 °C / 100.4 °F)~* Hypercalcemia (\>1mg/dl above ULN)~* Positive pregnancy test in female patients~* Lactating females~* Patients of childbearing potential unwilling to implement adequate birth control~* Patients whose actual body weight exceeds 175% of their ideal body weight~* History of ventricular arrhythmias~* Patient received thalidomide within 10 days prior to receiving the first dose of plerixafor~* Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Participants with Multiple Myeloma (MM) (Type: EXPERIMENTAL): Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).